Patent ID: 8980557
Filing Date: 2015-03-17
Classification: A61K,A61P,C12Q,G01N,G16H,Y02A

Abstract:
1. A method for determining the therapeutic response of a subject having colorectal cancer to which a FOLFOX6 regimen is administered the method comprising administering anti-cancer agents according to said FOLFOX6 regimen to said subject; obtaining a sample from said subject; measuring the expression level of ALAD gene, C20orf43 gene, GDA gene, TMEM18 gene, and UGT2B10 gene in said sample to determine the best tumor response (ratio) wherein the best tumor response (ratio) is calculated by measuring the expression level of ALAD gene, C20orf43 gene, GDA gene, TMEM18 gene, and UGT2B10 gene and then applying the formula: wherein A represents an expression level of ALAD gene; B represents an expression level of C20orf43 gene; C represents an expression level of GDA gene; D represents an expression level of TMEM18 gene; and E represents an expression level of UGT2B10 gene; correlating the best tumor response (ratio) to sensitivity to said FOLFOX6 regimen wherein when the obtained value is equal to or higher than a predetermined reference value, the cancer has sensitivity to the FOLFOX6 regimen, whereas when the obtained value is lower than the reference value, the cancer has no sensitivity to the FOLFOX6 regimen; and either continuing administration of the FOLFOX6 regimen if sensitivity is determined to be present or discontinuing administration of the FOLFOX6 regimen if sensitivity is determined to be absent.